USC and Tempus collaborate to create platform bridging patient care, clinical trials, and research

Sylvester researchers discover pathway that could explain prostate cancer resistance to ADT treatment

Researchers have discovered a previously unknown pathway that could explain why androgens remain and prostate cancer progresses despite treatment with androgen deprivation therapy.

December 12, 2025

Vol.51 No.45

Clinical Roundup

Five genes linked to aggressive prostate cancer in men of African descent, USC study identifies

Prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and treatment for patients of African ancestry.

November 07, 2025

Vol.51 No.41

Clinical Roundup

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

Using cell cultures and animal models, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC showed that next-generation CAR T cells can safely and effectively shrink solid tumors.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to research led by researchers at Keck Medicine of USC.

July 11, 2025

Vol.51 No.27

Clinical Roundup

USC team develops analytical tool to advance CAR T-cell therapy research

A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen receptor T cells, including how they evolve during manufacturing and which ones are most effective at killing cancer.

May 02, 2025

Vol.51 No.17

Clinical Roundup

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Researchers from the USC Norris Comprehensive Cancer Center found evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases. The study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer.

November 15, 2024

Vol.50 No.43

USC and Tempus collaborate to create platform bridging patient care, clinical trials, and research

YOU MAY BE INTERESTED IN

Sylvester researchers discover pathway that could explain prostate cancer resistance to ADT treatment

Five genes linked to aggressive prostate cancer in men of African descent, USC study identifies

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

USC team develops analytical tool to advance CAR T-cell therapy research

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Renew today!

Subscriber content

Never miss an issue!

Login